Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives.
暂无分享,去创建一个
[1] M. Lambert,et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α , 1997, Nature.
[2] H. Lassmann,et al. TNF-α receptor fusion protein prevents experimental auto-immune encephalomyelitis and demyelination in Lewis rats: an overview , 1997, Journal of Neuroimmunology.
[3] H. McFarland,et al. Complexities in the Treatment of Autoimmune Disease , 1996, Science.
[4] W. Heath,et al. Induction of Autoimmune Diabetes by Oral Administration of Autoantigen , 1996, Science.
[5] G. Kaplan,et al. Thalidomide as an anti-TNF-α inhibitor: Implications for clinical use , 1996 .
[6] S. Baqar,et al. Oral cytokine administration. , 1996, Immunology today.
[7] S. Medendorp,et al. Interferon beta induces interleukin‐10 expression: Relevance to multiple sclerosis , 1996, Annals of neurology.
[8] L. Wilkins. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b , 1996, Neurology.
[9] D. Paty,et al. Guidelines for physicians with patients on IFN beta-1b , 1996, Neurology.
[10] D. Bourdette,et al. Treatment of multiple sclerosis with T–cell receptor peptides: Results of a double–blind pilot trial , 1996, Nature Medicine.
[11] Christian Confavreux,et al. Clinical outcomes assessment in multiple sclerosis , 1996, Annals of neurology.
[12] C. Martínez-A,et al. Linomide prevents the lethal effect of anti-Fas antibody and reduces Fas-mediated ceramide production in mouse hepatocytes. , 1996, The Journal of clinical investigation.
[13] C. Mackay,et al. Chemokine receptors and T cell chemotaxis , 1996, The Journal of experimental medicine.
[14] P. Kiener,et al. Cytokine activation sensitizes human monocytic and endothelial cells to the cytotoxic effects of an anti-CD40 immunotoxin. , 1996, Journal of immunology.
[15] Nitin J. Karandikar,et al. CTLA-4: a negative regulator of autoimmune disease , 1996, The Journal of experimental medicine.
[16] D. Topham,et al. Vaccination with peptides from MHC class II beta chain hypervariable region causes allele-specific suppression of EAE , 1996, Journal of Neuroimmunology.
[17] A. Thompson,et al. New treatments for multiple sclerosis: a clinical perspective , 1996, Current opinion in neurology.
[18] P. Linsley,et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways , 1996, Nature.
[19] L. Nencioni,et al. Nerve Growth Factor Is an Autocrine Survival Factor for Memory B Lymphocytes , 1996, Cell.
[20] E. Shevach,et al. IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease. , 1996, Immunology today.
[21] L. Picker,et al. Lymphocyte Homing and Homeostasis , 1996, Science.
[22] C. Dinarello,et al. Biologic basis for interleukin-1 in disease. , 1996, Blood.
[23] C. Granger,et al. Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.
[24] A. Vandenbark,et al. T cell receptor peptides in treatment of autoimmune disease: Rationale and potential , 1996, Journal of neuroscience research.
[25] J. Ihle. STATs: Signal Transducers and Activators of Transcription , 1996, Cell.
[26] B. Nag,et al. Antigen‐Specific apoptosis in immortalized T cells by soluble MHC class II‐peptide complexes , 1996, Immunology and cell biology.
[27] D. Golde,et al. Soluble cytokine receptors. , 1996, Blood.
[28] T. Friedmann. Human gene therapy — an immature genie, but certainly out of the bottle , 1996, Nature Medicine.
[29] D. Bourdette,et al. Selective depletion of myelin–reactive T cells with the anti–OX–40 antibody ameliorates autoimmune encephalomyelitis , 1996, Nature Medicine.
[30] P. Allen,et al. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. , 1996, Annual review of immunology.
[31] E. Kinnunen. [Beta interferon and multiple sclerosis]. , 1996, Duodecim; laaketieteellinen aikakauskirja.
[32] E. Vitetta,et al. Immunotoxins: an update. , 1996, Annual review of immunology.
[33] F. Ramsdell,et al. Fas and FasL in the homeostatic regulation of immune responses. , 1995, Immunology today.
[34] J. Stavnezer. Regulation of antibody production and class switching by TGF-beta. , 1995, Journal of immunology.
[35] N. Hogg,et al. Structure and function of adhesion receptors in leukocyte trafficking. , 1995, Immunology today.
[36] G. Randolph,et al. Chemokines and tissue injury. , 1995, The American journal of pathology.
[37] L. Moldawer,et al. Human tumor necrosis factor receptor (p55) and interleukin 10 gene transfer in the mouse reduces mortality to lethal endotoxemia and also attenuates local inflammatory responses , 1995, The Journal of experimental medicine.
[38] J. Cleveland,et al. Contenders in FasL/TNF death signaling , 1995, Cell.
[39] A. Waisman,et al. Major T-cell responses in multiple sclerosis. , 1995, Molecular medicine today.
[40] T. Taniguchi. Cytokine signaling through nonreceptor protein tyrosine kinases. , 1995, Science.
[41] A. Sette,et al. Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. , 1995, Immunity.
[42] S. Miller,et al. Evolution of the T‐Cell Repertoire during the Course of Experimental Immune‐Mediated Demyelinating Diseases , 1995, Immunological reviews.
[43] S. Nagata,et al. The Fas death factor , 1995, Science.
[44] R. Simone,et al. The Costimulatory Molecule B7 is Expressed on Human Microglia in Culture and in Multiple Sclerosis Acute Lesions , 1995, Journal of neuropathology and experimental neurology.
[45] A. Fontana,et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis , 1995, Nature Medicine.
[46] R. Kinkel,et al. The interferons: Biological effects, mechanisms of action, and use in multiple sclerosis , 1995, Annals of neurology.
[47] S. Endres,et al. Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids , 1995, European journal of immunology.
[48] D. Madden. The three-dimensional structure of peptide-MHC complexes. , 1995, Annual review of immunology.
[49] K. Bendtzen,et al. Cytokines and autoantibodies to cytokines , 1995, Stem cells.
[50] M. Schwartz,et al. Integrins: emerging paradigms of signal transduction. , 1995, Annual review of cell and developmental biology.
[51] L. Jacobs,et al. A brief history of the use of interferons as treatment of multiple sclerosis. , 1994, Archives of neurology.
[52] K. Jellinger,et al. Patterns of oligodendroglia pathology in multiple sclerosis. , 1994, Brain : a journal of neurology.
[53] A. Minty,et al. Macrophage-inactivating IL-13 suppresses experimental autoimmune encephalomyelitis in rats. , 1994, Journal of Immunology.
[54] D. Hanley,et al. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains , 1994, Annals of neurology.
[55] H. Lassmann,et al. Experimental autoimmune panencephalitis and uveoretinitis transferred to the Lewis rat by T lymphocytes specific for the S100 beta molecule, a calcium binding protein of astroglia , 1994, The Journal of experimental medicine.
[56] M. Gerhart,et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing , 1994, Nature.
[57] C. Raine,et al. Multiple sclerosis: immune system molecule expression in the central nervous system. , 1994, Journal of neuropathology and experimental neurology.
[58] J. Goverman,et al. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. , 1994, Science.
[59] W. Paul,et al. Lymphocyte responses and cytokines , 1994, Cell.
[60] T. Springer. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm , 1994, Cell.
[61] S. Romagnani. Lymphokine production by human T cells in disease states. , 1994, Annual review of immunology.
[62] R. Bast,et al. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. , 1994, Nature.
[63] G. Kroemer,et al. Linomide, a novel immunomodulator that prevents death in four models of septic shock , 1993, European journal of immunology.
[64] Y. Cheng,et al. Antisense oligonucleotides as therapeutic agents--is the bullet really magical? , 1993, Science.
[65] S. Sriram,et al. Experimental allergic encephalomyelitis: Neutralizing antibody to TGFβ1 enhances the clinical severity of the disease , 1993, Journal of Neuroimmunology.
[66] H. Lassmann,et al. T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system , 1993, European journal of immunology.
[67] A. Lanzavecchia. Identifying strategies for immune intervention. , 1993, Science.
[68] D. Li,et al. Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.
[69] H. Weiner,et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. , 1993, Science.
[70] K. Tracey,et al. Tumor necrosis factor, other cytokines and disease. , 1993, Annual review of cell biology.
[71] A. Miller,et al. Dominance and crypticity of T cell antigenic determinants. , 1993, Annual review of immunology.
[72] S. Snyder,et al. Nitric oxide, a novel biologic messenger , 1992, Cell.
[73] F. Sánchez‐Madrid,et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin , 1992, Nature.
[74] D. Wallach,et al. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors , 1992, The Journal of experimental medicine.
[75] F. Sánchez‐Madrid,et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. , 1992, Nature.
[76] P. Vassalli,et al. The pathophysiology of tumor necrosis factors. , 1992, Annual review of immunology.
[77] Kenneth P. Johnson,et al. Immunotherapy of multiple sclerosis , 1991, Journal of Neuroimmunology.
[78] B. Weinshenker,et al. An open trial of OKT3 in patients with multiple sclerosis , 1991, Neurology.
[79] M. Jäättelä. Biologic activities and mechanisms of action of tumor necrosis factor-alpha/cachectin. , 1991, Laboratory investigation; a journal of technical methods and pathology.
[80] C. Brosnan,et al. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. , 1991, The Journal of clinical investigation.
[81] H. Lassmann,et al. Inflammation in the nervous system. Basic mechanisms and immunological concepts. , 1991, Revue neurologique.
[82] P. Sperryn,et al. Blood. , 1989, British journal of sports medicine.
[83] B. Beutler,et al. The biology of cachectin/TNF--a primary mediator of the host response. , 1989, Annual review of immunology.
[84] B. Beutler,et al. Cachectin: more than a tumor necrosis factor. , 1987, The New England journal of medicine.
[85] W. Popik. [Transforming growth factors]. , 1987, Postepy biochemii.
[86] C. Brosnan,et al. Prazosin treatment during the effector stage of disease suppresses experimental autoimmune encephalomyelitis in the Lewis rat. , 1986, Journal of immunology.
[87] B. Zweiman,et al. Isolation of myelin basic protein-reactive T-cell lines from normal human blood. , 1983, Cellular immunology.
[88] H. Hendrickson. Prevention of what? , 1983, Journal of the American Optometric Association.
[89] H. Mcdevitt,et al. In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[90] R. Wührich. [Treatment of multiple sclerosis]. , 1976, Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis.
[91] F. Roncaroli,et al. Neuropathology of multiple sclerosis , 2012 .
[92] L. Spitler,et al. EXPERIMENTAL ALLERGIC ENCEPHALITIS , 1972, The Journal of experimental medicine.
[93] M. Woodruff,et al. Immune Response , 1969, Nature.
[94] Diana Crane,et al. Science of Science , 1967, Nature.
[95] W. L. Benedict,et al. Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.
[96] C. Lumsden. Experimental allergic encephalomyelitis. , 1949, Brain : a journal of neurology.